BioCardia Inc logo

BCDA - BioCardia Inc News Story

$4.37 -0.2  -5.0%

Last Trade - 6:14pm

Small Cap
Market Cap £55.3m
Enterprise Value £39.9m
Revenue £110k
Position in Universe 5554th / 6946

BioCardia Signs Agreement with Leading Japanese Biotechnology Company for Catheter Biotherapeutic Delivery Product Candidates

Mon 26th April, 2021 1:00pm
For best results when printing this announcement, please click on link below:

SAN CARLOS, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc.
( [Nasdaq:
BCDA], today announced that it has entered into an agreement with a leading
Japanese biotechnology company related to BioCardia Helix catheter
biotherapeutic delivery product candidates.  Under the terms of the
agreement, BioCardia will receive $500,000, a portion of which is creditable
for biotherapeutic delivery products and support services. The agreement has a
one-year term with an option to negotiate for a non-exclusive world-wide
license to BioCardia Helix catheter biotherapeutic delivery product candidates
for certain cell types for cardiac indications.   

“Our collaboration with this leading Japanese biotechnology company further
validates our core Helix biotherapeutic delivery technology as the leading
delivery platform for local cell, gene and protein-based therapy to the
heart.  This is the first partnered program that is anticipated to benefit
from one of our newer delivery catheter technologies and our goal is to
continue this collaboration through clinical development to commercialization
by this new partner,” said BioCardia CEO Peter Altman, Ph.D. “Recent
publications have demonstrated our leading Helix delivery platforms best in
class efficiency((1),) and clinical performance((2)(,3)()).  These Helix
system advantages are believed to underlie our recently reported CardiAMP™
cell therapy clinical results in heart failure(()(4)()). We look forward to
bringing all of our experience and delivery technologies to bear to help
advance this new partner’s important therapeutic development efforts.”
1. Mitsutake Y, Pyun WB, Rouy D, et al. Improvement of local cell delivery
using Helix transendocardial delivery catheter in a porcine heart. Int Heart
J. (2017). 
2. Raval AN, Pepine CJ. Clinical safety profile of transendocardial catheter
injection systems: A plea for uniform reporting. Cardiovascular
Revascularization Medicine (2020).
3. Duckers, HJ, Ravel AN, Pepine, CJ, Johnston, PV, Traverse JH, Emery, J,
Miller, L, Abraham, WT, Altman, PA. Performance of Helix transendocardial
biotherapeutic delivery system after 300 cases. Presented at the Annual
Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.
4. Raval AN, Johnston PV, Duckers HJ, et al. Point of care, bone marrow
mononuclear cell therapy in ischemic heart failure patients personalized for
cell potency: 12-month feasibility results from CardiAMP heart failure roll-in
cohort, Int J. Cardiology (2020).
About BioCardia®
BioCardia, Inc.
headquartered in San Carlos, California, is developing regenerative biologic
therapies to treat cardiovascular and pulmonary disease. CardiAMP™
autologous and NK1R+ allogeneic cell therapies are the Company’s
biotherapeutic product candidates in clinical development. The Company's
current products include the Helix™ transendocardial delivery system, the
Morph® steerable guide and sheath catheter portfolio and the AVANCE™
steerable introducer family. BioCardia also partners with other biotherapeutic
companies to provide its Helix systems and development support to their
programs studying therapies for the treatment of heart failure, chronic
myocardial ischemia and acute myocardial infarction.

Forward Looking Statements:
This press release contains forward-looking statements that are subject to
many risks and uncertainties. Forward-looking statements include, among other
things, performance of our delivery systems, success of the collaboration, and
revenues to be received from the collaboration agreement described. These
forward-looking statements are made as of the date of this press release, and
BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify these
forward-looking statements. Although we believe that we have a reasonable
basis for each forward-looking statement contained herein, we caution you that
forward-looking statements are not guarantees of future performance and that
our actual results may differ materially from the forward-looking statements
contained in this press release. As a result of these factors, we cannot
assure you that the forward-looking statements in this press release will
prove to be accurate.  Additional factors that could materially affect actual
results can be found in BioCardia’s Form 10-K filed with the Securities and
Exchange Commission on March 30, 2021, under the caption titled “Risk
Factors.” BioCardia expressly disclaims any intent or obligation to update
these forward-looking statements, except as required by law. 

Media Contact:
Michelle McAdam, Chronic Communications, Inc.
Phone: 310-902-1274

Investor Contact:
David McClung, Chief Financial Officer
Phone: 650-226-0120


GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.